Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHVSBullishIndustry Newsnews

High materiality8/10

Real-world HAE study highlights gaps, boosting case for Pharvaris oral therapy

Oct 5, 2026, 6:53 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Independent real-world data supporting patient preference for oral LTP reinforces demand for Pharvaris’ oral candidates and could improve near-term investor sentiment and payer discussions, potentially aiding regulatory/commercial progress.

AI summary

What happened, with direct paths to the underlying reporting

Pharvaris-funded Adelphi Real World HAE DSP analysis across the US, Europe, and Japan (Jan 2023–Jan 2024) finds gaps between guideline care and real practice. Patients favor daily oral LTP; on-demand therapy is underutilized due to burden and access, underscoring demand for Pharvaris’ oral deucrictibant candidates and potential payer support.

Pharvaris-funded real-world HAE DSP analysis published. Highlights gaps between guideline care and practice.
Data from 225 physicians and 1,131 patients across US/Europe/Japan. Survey period Jan 2023–Jan 2024.
Daily oral long-term prophylaxis (LTP) preferred; injections burden adherence.
On-demand treatment often underutilized due to perceived severity and availability.
Findings inform Pharvaris’ strategy and potential product development.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.